Kura Oncology Inc is a clinical-stage biopharmaceutical company. Operating globally, its main focus is advancing therapies for patients with solid tumours and blood cancers.
The company operates in the biotechnology sector, developing novel precision medicines that aim to prevent tumours developing resistance through smart treatment combinations. Kura Oncology Inc has a pipeline of small-molecule product candidates that target cancer signalling pathways in cancers with high unmet need, including lung, pancreatic and blood cancers such as leukaemia.
Keep up to date on the latest share price changes by adding KURA stock to your eToro watchlist.